 The FDA has issued a clinical hold on PolarityTE Incs NASDAQ: PTE SkinTE Investigational New Drug Application IND for chronic cutaneous ulcers. The FDA provided feedback on certain Chemistry, Manufacturing, and Control CMC items that need to be addressed before proceeding with a pivotal study. 